论文部分内容阅读
目的探讨白血病相关免疫表型在非M3急性髓细胞性白血病(非M3-AML)中的表达及预后意义。方法应用流式细胞仪检测147例非M3-AML患者白血病相关表型特征的表达,同时与外周血白细胞计数、骨髓增殖异常综合征病史或多系病态造血、染色体核型及老年等预后相关因素及临床完全缓解率进行比较。结果 CD33+CD7+和(或)CD33+CD19+(跨系列表达)者55例(37.4%),CD34与CD11b共表达(跨阶段表达)者65例(44.2%);发病时外周血白细胞计数>25×109/L者52例(35.4%);124例患者进行了标准化疗,经两个疗程后达到完全缓解者70例(56.5%)。经Logistic回归显示临床完全缓解状况与CD34与CD11b共表达密切相关(OR=0.489,P=0.000)。结论非M3-AML白血病细胞CD34与CD11b共表达与临床缓解率低密切相关,为临床预后不良的指标。
Objective To investigate the expression and prognostic significance of leukemia-associated immunophenotype in non-M3 acute myeloid leukemia (non-M3ML). Methods Flow cytometry was used to detect the expression of leukemia-related phenotypes in 147 cases of non-M3ML AML patients. Meanwhile, they were correlated with peripheral blood leukocyte count, history of myelodysplastic syndromes or pathological hematopoiesis, chromosome karyotypes, and age-related prognosis And clinical complete remission rate were compared. Results 55 (37.4%) were CD33 + CD7 + and / or CD33 + CD19 + (cross-lineage) and 65 (44.2%) were CD34 and CD11b co- Fifty-two patients (35.4%) had x 109 / L; 124 patients underwent standard chemotherapy and 70 patients (56.5%) achieved complete remission after two courses of treatment. Logistic regression showed that the clinical complete remission status was closely related to the co-expression of CD34 and CD11b (OR = 0.489, P = 0.000). Conclusion The co-expression of CD34 and CD11b in non-M3ML leukemia cells is closely related to the low clinical remission rate, which is an indicator of poor clinical prognosis.